Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma 16-10-2023, 19:21

RH CPAs Chief Visionary Officer Leon Rives Announces New 17-02-2023, 22:32

WHR Introduces New Enterprise Business Intelligence Tool to Serve Clients 7-03-2023, 21:16